Since ALDH1L1 is targeted by disulfiram,10 we combined disulfiram and polatuzumab vedotin in four DLBCL cell lines, selected for their different degrees of sensitivity to the ADC: two polatuzumab vedotin‐resistant (the ABC DLBCL SU‐DHL‐2 and RCK8) and two polatuzumab vedotin‐sensitive models (the ABC DLBCL RIVA and the GCB DLBCL SU‐DHL‐16). This evidence concerns the gene ALDH1L1 and diffuse large B-cell lymphoma.